WALD

Waldencast PLC

Add to Watchlist

Advanced Chart

3.080

+0.56(22.222%)1D

Line

Candle

YTD

High

3.150

Open

2.510

VWAP

2.92

Vol

320.03K

Mkt Cap

378.87M

Low

2.420

Amount

936.03K

EV/EBITDA(TTM)

Total Shares

122.19M

598.31M

EV/OCF(TTM)

P/S(TTM)

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

81.38M

+12.9%

77.63M

+10.57%

Estimates Revision

The market is revising No Change the revenue expectations for Waldencast plc (WALD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 78.03%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+78.03%

In Past 3 Month

4 Analyst Rating

8.12% Upside

Wall Street analysts forecast WALD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WALD is 3.33 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

2 Hold

0 Sell

Moderate Buy

8.12% Upside

Current: 3.080

Low

2.00

Averages

3.33

High

5.00

8.12% Upside

Current: 3.080

Low

2.00

Averages

3.33

High

5.00

TD Cowen

Jonna Kim

Hold

downgrade

2025-08-20

Reason

TD Cowen

Jonna Kim

Price Target

2025-08-20

downgrade

Hold

Reason

TD Cowen analyst Jonna Kim lowered the firm's price target on Waldencast to $2 from $2.40 and keeps a Hold rating on the shares. The firm noted the company launched an exploration of strategic alternatives and has postponed reporting 1H25. Key 2Q positives are sell-through momentum at Milk in the US and the core business at Obagi sequentially improving.

Telsey Advisory

Outperform

NULL

downgrade

$4 -> $3

2025-08-20

Reason

Telsey Advisory

Price Target

$4 -> $3

2025-08-20

downgrade

Outperform

NULL

Reason

Telsey Advisory lowered the firm's price target on Waldencast to $3 from $4 and keeps an Outperform rating on the shares. The moderated annual outlook comes as a disappointment as solid underlying trends are offset by softening international consumption, out of stocks at its brands, and exiting of non-core distribution points at Obagi, the analyst tells investors.

Canaccord

Buy

downgrade

$6 -> $5

2025-05-15

Reason

Canaccord

Price Target

$6 -> $5

2025-05-15

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Waldencast to $5 from $6 and keeps a Buy rating on the shares. The firm said Waldencast reported 1Q sales that were down citing supply chain and comp issues that hindered results. However, they did note brand demand saw an acceleration exiting the quarter.

Alliance Global Partners

Buy

maintain

2025-05-15

Reason

Alliance Global Partners

Price Target

2025-05-15

maintain

Buy

Reason

Alliance Global Partners lowered the firm's price target on Waldencast to $4.50 from $5 and keeps a Buy rating on the shares following the Q1 report. The firm is encouraged to see lower legal fees, but views that as partially negated given the lower profits. It acknowledges evidence of accelerated growth will need be seen in Q2 for investors to gain greater confidence in Waldencast's outlook and growth initiatives that include innovation in the pipeline, new digital channels, continued expansion of its retail footprint and improved product availability.

Telsey Advisory

Dana Telsey

Outperform

downgrade

$5 -> $4

2025-05-15

Reason

Telsey Advisory

Dana Telsey

Price Target

$5 -> $4

2025-05-15

downgrade

Outperform

Reason

Telsey Advisory analyst Dana Telsey lowered the firm's price target on Waldencast to $4 from $5 and keeps an Outperform rating on the shares. While not entirely unexpected, FY25 has started out relatively challenging, the analyst tells investors. While margin and distribution expansion opportunities exist for its Milk Makeup brand, the firm is moderating its price target given incremental risks to the global macro outlook.

Alliance Global Partners

Aaron Grey

Strong Buy

Initiates

2025-04-22

Reason

Alliance Global Partners

Aaron Grey

Price Target

2025-04-22

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Waldencast PLC (WALD.O) is -6.16, compared to its 5-year average forward P/E of 16.50. For a more detailed relative valuation and DCF analysis to assess Waldencast PLC 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

16.50

Current PE

-6.16

Overvalued PE

151.14

Undervalued PE

-118.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

13.96

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

18.66

Undervalued EV/EBITDA

9.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.10

Current PS

0.00

Overvalued PS

3.13

Undervalued PS

1.08

Financials

Annual

Quarterly

FY2025Q1

65.44M

Total Revenue

FY2025Q1

N/A

Operating Profit

FY2025Q1

N/A

Net Income after Tax

FY2025Q1

N/A

EPS - Diluted

FY2022Q2

YoY :

-461.85%

-11.27M

Free Cash Flow

FY2025Q1

72.13

Gross Profit Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

WALD News & Events

Events Timeline

2025-11-16 (ET)

2025-11-16

11:11:36

Waldencast's Obagi Medical to Showcase New Findings at ASDS Annual Conference

2025-11-14 (ET)

2025-11-14

17:09:39

Waldencast transfers 'Obagi' trademark rights in Japan to Rohto for $82.5 million

2025-10-08 (ET)

2025-10-08

08:07:17

Obagi Medical Introduces Nu-Cil BioStim Scalp Serum

News

9.0

11-16Yahoo Finance

Obagi Medical Presents New Clinical Findings on Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting